A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Psilocybin is gaining popularity as research shows potential benefits to those with anxiety, depression, and other mental health conditions. Individuals with risk factors for psychosis are typically excluded from such studies, limiting the empiric research of the risks and benefits in vulnerable populations. In the real-world setting, many individuals who seek treatment with psilocybin will have comorbid psychiatric conditions and other factors that predispose them to psychosis. We report a case of a patient with multiple predisposing risk factors, including a history of depression, personality disorder traits, and cannabis use, who experienced a psychotic episode with catatonic features and suicidality after several months of heavy psilocybin use. A review of similar previously published case reports demonstrates a pattern of psilocybin-induced psychosis occurring primarily in individuals with predisposing factors who have consumed either high or repeated doses of the drug. This case report furthers this pattern, which serves as both a warning that psilocybin use is not without risks and reassurance for researchers using much lower doses to treat mental illness.
Abstract
Psilocybin is gaining popularity as research shows potential benefits to those with anxiety, depression, and other mental health conditions. Individuals with risk factors for psychosis are typically excluded from such studies, limiting the empiric research of the risks and benefits in vulnerable populations. In the real-world setting, many individuals who seek treatment with psilocybin will have comorbid psychiatric conditions and other factors that predispose them to psychosis. We report a case of a patient with multiple predisposing risk factors, including a history of depression, personality disorder traits, and cannabis use, who experienced a psychotic episode with catatonic features and suicidality after several months of heavy psilocybin use. A review of similar previously published case reports demonstrates a pattern of psilocybin-induced psychosis occurring primarily in individuals with predisposing factors who have consumed either high or repeated doses of the drug. This case report furthers this pattern, which serves as both a warning that psilocybin use is not without risks and reassurance for researchers using much lower doses to treat mental illness.
참고문헌 (14)
- Johnson M, "Human hallucinogen research : guidelines for safety", J Psychopharmacol, 22, pp.603~620 (2008)
- Sienaert P, "Measuring catatonia : a systematic review of rating scales", J Affect Disord, 135, pp.1~9 (2011)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
- Suleiman M, "From mushrooms to myolysis : a case of rhabdo in psilocybin-induced mood and psychotic disorder", J Nerv Ment Dis, 210, pp.638~639 (2022)
- Barber G, "A case of prolonged mania, psychosis, and severe depression after psilocybin use : implications of increased psychedelic drug availability", Am J Psychiatry, 179, pp.892~896 (2022)
- Hendin HM, "An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder : a case report", Bipolar Disord, 23, pp.733~735 (2021)
- Bickel M, "Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after ‘magic mushroom’ abuse", Eur J Emerg Med, 12, pp.306~308 (2005)
- Nielen RJ, "Khat and mushrooms associated with psychosis", World J Biol Psychiatry, 5, pp.49~53 (2004)
- Dewhurst K, "Psilocybin intoxication", Br J Psychiatry, 137, pp.303~304 (1980)
- Davies NS, "Psychiatric symptoms and hallucinogenic compounds", Br Med J, 2, pp.797~ (1979)
- Hyde C, "Abuse of indigenous psilocybin mushrooms : a new fashion and some psychiatric complications", Br J Psychiatry, 132, pp.602~604 (1978)
- Simonsen E, "Personality pathology and schizophrenia", Schizophr Bull, 44, pp.1180~1184 (2018)
- Ortiz-Medina MB, "Cannabis consumption and psychosis or schizophrenia development", Int J Soc Psychiatry, 64, pp.690~704 (2018)
- Lowe H, "The therapeutic potential of psilocybin", Molecules, 26, pp.2948~ (2021)